Abiomed (NSDQ:ABMD) said today it won FDA pre-market approval for its next-gen Impella CP heart pump with the SmartAssist optical sensor, and announced late last week that it named Todd Trapp its new CFO.
The newly cleared Impella CP with SmartAssist features improvements intended to simplify patient management, integrate clinical data informatics including left ventricular pressure, end-diastolic pressure and cardiac power output, and improve ease of use during set up and monitoring, the Danvers, Mass.-based company said.
“The ability to view fundamental hemodynamic data such as LVP, EDP and CPO directly on the Impella console provides critical information for clinical decision-making. Additionally, access to data and real-time pump position improves efficiency for nurses and physicians in the ICU and CCU,” William O’Neill of the Henry Ford Hospital said in a prepared statement.
Abiomed said it has already received CE Mark approval in the European Union for its Impella CP with SmartAssist, and added that more than 60 patients at three sites have been treated with the next-gen Impella CP.
“Abiomed would like to thank our physicians, technologists and nurses for their feedback on how to improve the Impella platform. Our scientists, engineers and clinical team are always looking for ways to improve our ease of use, training and clinical performance. Through innovation and research, our clinical team will utilize SmartAssist to help our customers achieve our goal to improve outcomes and enable heart recovery for every patient,” chair & CEO Michael Minogue said in a press release.
The company also announced that former Watts Water Tech CFO Trapp is joining as its new CFO. Prior to working with Watts Water Tech, Trapp spent 13 years with Honeywell International as financial planning and analysis VP and airlines biz unit CFO.
“I am very excited to join Abiomed, a company that has and continues to revolutionize patient care with its world class Impella technology. I am committed to working closely with the employees and shareholders to further grow the company and continue Abiomed’s tradition of strong execution,” Trapp said in prepared remarks.
“After an extensive search, we are pleased to welcome Todd Trapp to our executive team at Abiomed. Todd’s impressive proven record of accomplishment as a global CFO exemplifies his financial expertise, operational discipline and leadership. Todd will help Abiomed rise to the next level for the patients that we serve and our shareholders,” CEO Minogue said in a prepared release.